Two experimental drug molecules promoted myelin repair in MS disease models, pointing toward a possible future route for ...
eMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, ...
The first participant has been dosed in an investigator-led Phase 2 trial testing pegsebrenatide as a potential treatment for ...
A single 25-mg dose of psilocybin was associated with lasting anatomical brain changes, an imaging study of 28 healthy, ...
Neuraly, Inc., a wholly owned subsidiary of D&D Pharmatech, Inc. (KOSDAQ: 347850), announced that the first patient has been dosed in a Phase 2 Investigator-Initiated Trial (IIT) evaluating ...
Multiple sclerosis (MS) is most prevalent in Northern Europe and Canada, and more common in the northernmost latitudes. In ...
Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K. Manji, Eric J. Nestler, and Patrick J. Kennedy.
Results consistent with pre-clinical studies demonstrating that, in the early stages of the neurodegenerative process, disease progression in the basal forebrain is reversible Findings also correlate ...
The University of Michigan's President-elect Kent Syverud is being treated for brain cancer and will not take over as president as scheduled next month. "It is with a heavy heart and with Kent's ...
We are thrilled that our Phase 2a study of intranasal foralumab in Multiple System Atrophy has been selected as a late-breaking poster at the 7th World Parkinson Congress,” said Ivor Elrifi, CEO of ...
Laura holds a Master's in Experimental Neuroscience and a Bachelor's in Biology from Imperial College London. Her areas of expertise include health, medicine, psychology, and neuroscience. Laura holds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results